Proteomics-based anticancer drug discovery and development.
Proteins are important targets for drug discovery and this applied to cancer as well because there is a defect in the protein machinery of the cell in malignancy. Proteomic technologies are now being integrated with genomic approaches for cancer drug discovery and target validation. Among the large number of proteomic technologies available for this purpose, the most important ones are 3-D protein structure determination, protein microarrays, laser capture microdissection and study of protein-protein and protein-drug interactions. Cancer biomarkers and several cell pathways are important drug targets. Several companies are involved in using proteomic technologies for drug discovery. Finally, proteomic approaches will play an important role in the discovery and development of personalized medicines.
Jain
K K
KK
Jain PharmaBiotech, Blaesiring 7, CH-4057 Basel, Switzerland. jain@pharmabiotech.ch
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001709:Biotechnology; D015195:Drug Design; D004345:Drug Industry / Q000639:trends; D006801:Humans; D007834:Lasers; D009369:Neoplasms / Q000378:metabolism; D040081:Protein Array Analysis; D011485:Protein Binding; D011487:Protein Conformation; D020543:Proteome
D000970:Antineoplastic Agents; D020543:Proteome